Massachusetts General Hospital
Corporate & Foundation Relations
Office of Development

FOUNDATION FUNDING OPPORTUNITIES: AUGUST 13, 2021

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

*Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.*

*The MGB **Proposal Deadline Policy** establishes internal deadlines for sponsored research proposals to ensure that submissions meet sponsor criteria and institutional/regulatory requirements. Deadlines are:*

- *The complete Administrative Components are due to Research Management (RM) on or before the **8th Business Day** by 5 PM.*
- *The Final (Science) Components are due to RM on or before the **3rd Business Day**.*

> **Have you updated your MGH Researcher profile?**
> **Go to https://researchers.mgh.harvard.edu/ today!**

Table of Contents

*Do you want to learn more about identifying external funding opportunities? Please click here to request a research consultation with **Amy Robb** or see ECOR's website for information on the Pivot database.*

12. [Parkinson's Pathway Molecular Data Analysis](#), The Michael J. Fox Foundation for Parkinson's Research (MJFF)
13. [Target Advancement Program](#), The Michael J. Fox Foundation for Parkinson's Research (MJFF)
14. [Therapeutic Pipeline Program: Pre-clinical Program](#), The Michael J. Fox Foundation for Parkinson's Research (MJFF)

1. Lawrence M. Brass Stroke Research Award, American Brain Foundation (ABF)/ American Academy of Neurology (AAN)
Funded by the American Heart Association and American Brain Foundation, this award aims to recognize the importance of good clinical research and to encourage early career investigators in clinical studies related to stroke, vascular neurology, and neurocritical care.

For the purpose of this scholarship, research is defined as "patient-oriented research conducted with human participants, or translational research specifically designed to develop treatments or enhance diagnosis of neurologic disease. These areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research." Disease-related studies not directly involving humans or human tissue are also encouraged if the primary goal is the development of therapies, diagnostic tests, or other tools to prevent or mitigate neurological diseases.

Eligibility requirements (partial list):
- Recipient must be an AAN member, or willing to join AAN if awarded funding.
- Have completed residency or a PhD no more than 5 years prior to the beginning of this award (July 1, 2022). If you have completed both residency and a PhD, your eligibility is based on when you completed residency. If you completed a fellowship of any kind after residency, your eligibility is still based on the date you finished residency.

Citizenship: Unrestricted

Award Amount: $150,000 for 1 years
Indirect Costs: None
Research Management Deadline: September 21, 2021
Application Deadline: October 1, 2021
Website: https://www.aan.com/education-and-research/research/aan-research-program/lawrence-m-brass-stroke-research-award/

2. Research Grants, Bruno and Ilse Frick Foundation for Research on ALS
The goal of the foundation is to provide research grants for the study of the understanding of the basic causes of ALS. These awards are not directed to clinically related projects for patient care.

The Frick Foundation is looking for talented early-career scientists who have already produced excellent supervised work, ready to work independently and shows potential to be a research leader. Research must be conducted in a public or private research organisation (known as a Host Institution/HI).

Eligibility requirements (partial list):
- Eligibility is open to researchers of any nationality with 5 years of experience since completion of their PhD, a scientific track record showing great promise and an excellent research proposal.

Citizenship: Unrestricted

Award Amount: 100,000 Swiss francs (≈ $108,000) paid over 2 years
Indirect Costs: Unspecified
Research Management Deadline: September 20, 2021
Application Deadline: September 30, 2021
Website: http://frick-fondation.ch/

3. Clinic and Laboratory Integration Program (CLIP) Grants, Cancer Research Institute (CRI)
The Cancer Research Institute established Clinic and Laboratory Integration Program to support investigators who are studying critical topics at the intersection of laboratory and clinical research in immuno-oncology.

CLIP Grants provide funding for qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The grant will support pre-clinical and translational research, which will provide information that can be directly applied to optimizing cancer immunotherapy in the clinic.

Proposals in all cancers are encouraged.

Citizenship: Unrestricted

Award Amount: $200,000 paid over 2 years
Indirect Costs: None
LOI Deadline: November 1, 2021
Research Management Deadline: December 3, 2021
(Invited) Application Deadline: December 15, 2021
Website: https://cancerresearch.org/scientists/fellowships-grants/translational-research-grants

4. Grants, Caplan Foundation for Early Childhood
The Caplan Foundation for Early Childhood is an incubator of promising research and development projects that appear likely to improve the welfare of young children, from infancy through 7 years, in the United States. Welfare is broadly defined to include physical and mental

health, safety, nutrition, education, play, familial support, acculturation, societal integration and childcare.

The Foundation provides funding in the following areas:

1. Early Childhood Welfare
Children can only reach their full potential when all aspects of their intellectual, emotional and physical development are optimally supported.

Providing a safe and nurturing environment is essential as is imparting the skills of social living in a culturally diverse world. Therefore, the Foundation supports projects that seek to perfect child rearing practices and to identify models that can provide creative, caring environments in which all young children thrive.

2. Early Childhood Education and Play
Research shows that children need to be stimulated as well as nurtured, early in life, if they are to succeed in school, work and life. That preparation relates to every aspect of a child's development, from birth to age seven, and everywhere a child learns - at home, in childcare settings and in preschool.

We seek to improve the quality of both early childhood teaching and learning, through the development of innovative curricula and research based pedagogical standards, as well as the design of imaginative play materials and learning environments.

3. Parenting Education
To help parents create nurturing environments for their children, we support programs that teach parents about developmental psychology, cultural child rearing differences, pedagogy, issues of health, prenatal care and diet, as well as programs which provide both cognitive and emotional support to parents.

Citizenship: United States

Award Amount: Unspecified
Indirect Costs: 15%
LOI Deadline: September 30, 2021
Website: http://earlychildhoodfoundation.org/

5. CARRA-Arthritis Foundation Large Grants, Childhood Arthritis and Rheumatology Research Alliance CARRA
This funding opportunity supports the development and publication of a clinical or translational project which will immediately impact research projects within CARRA or result in a larger collaborative grant that furthers the CARRA mission. New or early investigators are encouraged to apply and will be afforded special consideration. A successful application may be for:

- an all-inclusive clinical or translational research project; or
- a pilot research project, that if successful, could lead to extramural funding.

Eligibility requirements (partial list):
- The project PI must be a current CARRA member who is up to date on both membership dues and membership information (location, contact information, and membership status).
- An investigator may only receive one CARRA grant (large or small) per year (365 day period).
- MD applicants must be at faculty level.
- PhD and Masters level researchers, nurses and research coordinators are eligible to submit proposals.
- Priority will be given to new and/or early investigators.
- All grants must be submitted by or have a pediatric rheumatologist named as a Co-I.
- Fellows, residents, and CARRA Executive Committee members are not eligible.

Citizenship: Unrestricted

Award Amount: $50,000 for 1 year
Indirect Costs: 8%
LOI Deadline: September 1, 2021
Research Management Deadline: September 21, 2021
Application Deadline: October 1, 2021
Website: https://carragroup.org/members/grants-and-funding/carra-af-large-grants

6. Clinical Pilot and Feasibility Awards, Cystic Fibrosis Foundation (CFF)/Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT)
Clinical Research Awards are offered to provide support for investigator-initiated clinical research projects that have the potential to make an important contribution to the CF Foundation's mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of CF using clinical (observational/interventional), translational or epidemiologic study approaches.

Applications may address any topic area advancing CF care, treatment, or research. However, applications addressing the following areas are particularly encouraged:
- Respiratory microorganism detection and treatment
- Gastrointestinal symptoms (including, but not limited to, gastroesophageal reflux disease (GERD), Distal Intestinal Obstruction Syndrome (DIOS), and pancreatitis)
- Reducing treatment burden
- CF-related diabetes
- Diet and nutrition
- Mental health
- CF-related liver disease

- Exercise
- Sinus disease
- Allergies and asthma in CF
- Alternative/holistic treatments and therapies
- Sexual reproductive health
- Bone/joint health
- Pain management

Eligibility requirements (partial list):
- Applicants must be independent investigators.
- Applicants must hold faculty level positions. Fellows may submit applications; however, funding will only be considered if they will hold a faculty-level appointment at the time of the award.

Citizenship: Unrestricted

Award Amount: $160,000 paid over 2 years
Indirect Costs: 12%
LOI Deadline: August 16, 2021
Research Management Deadline: January 13, 2022
Application Deadline: January 25, 2022
Website: https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Research-Awards/Clinical-Pilot-and-Feasibility-Award/

7. Clinical Research Award, Cystic Fibrosis Foundation (CFF)

The intent of the Clinical Research Award program is to provide support for investigator-initiated clinical research projects that have the potential to make an important contribution to the Cystic Fibrosis Foundation's mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of cystic fibrosis, using clinical, translational, or epidemiologic study approaches.

The CF Foundation seeks applications for the Clinical Research Award from all areas of clinical research that will have an impact on the lives of people with CF. However, the following research areas are of particular interest to the CF Foundation as they will address critical needs of people with CF:
- Studies that investigate CF disease complications (lung, gastrointestinal (GI) tract, liver, pancreas, reproduction, mental health, endocrine, etc.)
- Strategies to improve care and quality of life of people with CF
- Assessment and validation of biomarkers, clinical trial tools, outcome measures, and efficacy endpoints
- Translational or clinical studies in lung transplant1 research
- Characterization of CF disease manifestations and management in the era of highly effective modulator therapy

- Novel interventions that improve CF patient care and outcomes
- Studies designed to translate laboratory findings of disease pathogenesis/treatment to clinical evaluation

Citizenship: Unrestricted

Award Amount:
- Up to $450,000 paid over 3 year for single-center clinical research awards
- Up to $1.05 million paid over 3 years for multi-center clinical research

Indirect Costs: 12%
LOI Deadline: August 16, 2021
Research Management Deadline: January 13, 2022
Application Deadline: January 25, 2022
Website: https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Research-Awards/Clinical-Research-Awards/

8. Research Grants, Foundation for Women's Cancer (FWC)/Society of Gynecologic Oncology
The FWC continues to seek additional funding to support expanded research priorities. Of special importance is increased funding for cervical, uterine, primary peritoneal, vaginal and vulvar cancer research.

St. Louis Ovarian Cancer Awareness Research Grant
$50,000 for 1 year
The Foundation gratefully acknowledges St. Louis Ovarian Cancer Awareness and Caring Together, Inc., of NY for their combined support of this grant. St. Louis Ovarian Cancer Awareness is committed to impacting ovarian cancer survivorship by promoting awareness of early warning signs and standards of care, funding ovarian cancer research, and supporting survivors. Caring Together, NY is dedicated to providing support, education, and advocacy for women with ovarian cancer and to supporting research efforts aimed at finding an early detection test and a cure.

Amy Krouse Rosenthal Foundation and Judy's Mission to End Ovarian Cancer Foundation Research Grant for Early Detection of Ovarian Cancer
$50,000 for 1 year
This grant is related to Ovarian Cancer with an emphasis on early detection. The Foundation gratefully acknowledges both the Amy Krouse Rosenthal Foundation and the Judith Liebenthal Robinson Ovarian Cancer Foundation for their combined support of this grant. The Amy Krouse Rosenthal Foundation focuses on early detection because they know that a woman's survival rate exponentially increases when ovarian cancer is caught early.

Laura Crandall Brown Foundation Ovarian Cancer Early Detection Research Grant
$50,000 for 1 year
This grant is related to Ovarian Cancer with an emphasis on early detection. The Foundation gratefully acknowledges the Laura Crandall Brown Foundation for support of this grant. Laura Crandall Brown Foundation offers hope through research for early detection of ovarian cancer, empowering communities through gynecologic cancer awareness, and enriching lives through support.

Wilma Williams Education and Clinical Research Award for Endometrial Cancer
$25,000 for 1 year
The Foundation gratefully acknowledges Dr. James Orr and Mrs. Vicki Orr for their support of this grant. This grant is intended to honor both Wilma Williams and the tireless work and dedication of all gynecologic oncologists, and to ensure the ability to pass on and preserve the specialized medical skills and tools to those physicians who will carry the torch.

ME STRONG Cervical Cancer Research Grant
$25,000 for 1 year
Related to cervical cancer biology aimed at novel therapies with an emphasis on immune component. The Foundation gratefully acknowledges ME STRONG for support of this grant. ME STRONG is a charity committed to serving Central Floridians battling cancer and to funding groundbreaking research in pursuit of a cure.

Grant in Honor of Dr. Ginger J. Gardner **NEW!**
$25,000 for 1 year
This grant is related to uterine cancer. The Foundation gratefully acknowledges Marcy Regan for support of this grant. This grant is intended to honor Dr. Ginger J. Gardner for the outstanding care given and her dedication to gynecologic oncology in her first year as Chair of the Foundation for Women's Cancer.

Grant in Memory of Peggy A. Yates **NEW!**
$50,000 for 1 year
This grant is related to all gynecologic cancers except ovarian cancer. No fetal tissue may be used when conducting this research. The Foundation gratefully acknowledges the family of Peggy A Yates for support of this grant.

Eligibility requirements (partial list):
- The Foundation will fund the best project applications, with priority given to young investigators. Young investigators are defined as those individuals who have not been previously funded by the Department of Defense, American Cancer Society or the National Cancer Institute in this area. Exceptions to these criteria may be made upon approval of the committee.
- SGO members who apply should be junior investigators, generally Assistant Professor and below. Priority will be given to junior investigators.

- Non-members of the Society of Gynecologic Oncology (SGO) may apply with a co-investigator who is an SGO member. The goal of such collaborative applications is to foster collaboration and mentorship of an investigator new to the field. It is important for the applicant to document this relationship.
- Significant overlap with existing funding is not permitted. Applicants should note the existence of pending applications with potential overlap and a plan for how such overlap would be managed if both applications were funded.

Citizenship: Unrestricted

Indirect Costs: 10%
Abstract Deadline: August 31, 2021
Research Management Deadline: December 9, 2021
(Invited) Proposal Deadline: December 21, 2021
Website: https://fwc.secure-platform.com/a/page/prizes-copy2020/awardofferings-2022

9. Charles H. Hood Foundation Child Health Research Awards Program, Health Resources in Action (HRiA)/The Medical Foundation

The Charles H. Hood Foundation was incorporated in 1942 to improve the health and quality of life for children through grant support of New England-based pediatric researchers. The intent of the Child Health Research Awards Program is to support newly independent faculty, provide the opportunity to demonstrate creativity, and assist in the transition to other sources of research funding.

Grants support hypothesis-driven clinical, basic science, public health, health services research, and epidemiology projects focused on child health.

Applicants will be asked to complete an impact statement describing the implications of their work. Basic science projects will describe project's relevance to child health or disease. For translational research, applicants will be asked to describe the next steps in moving the research along the translational research spectrum towards clinical application. For T4 or public health research, they will be asked to describe the implications for healthcare or public policy.

Resubmission policy:
- Every effort will be made to provide written feedback from the Committee to applicants, who will have the opportunity to reapply one time following an initial application and only during one of the next two semi-annual grant cycles immediately following the original submission. Please note that the resubmission will be considered alongside all other submissions received during that grant cycle; no special preference will be given to resubmissions.

Eligibility requirements (partial list):

- All applicants must have completed their training at the time of application and be within five years (for PhD scientists) and seven years (for physician-scientists) of employment following conclusion of training. Applications from physician-scientists are encouraged.
- All applicants must have a doctoral degree, lead independent research programs, hold a faculty appointment at a nonprofit academic, medical or research institution in the six New England states (Maine, Vermont, New Hampshire, Massachusetts, Rhode Island, and Connecticut) and be working in that institution by the application deadline.

Citizenship: Unrestricted

Award Amount: $165,000 paid over 2 years
Indirect Costs: 10%
Research Management Deadline: September 10, 2021
Application Deadline: September 22, 2021
Website: https://hria.org/tmf/hood/

10. Cellular Phenotyping in Human iPSCs, The Michael J. Fox Foundation for Parkinson's Research (MJFF) NEW!

This program will support phenotyping of human induced pluripotent stem cells (iPSCs) from our Parkinson's Progression Markers Initiative (PPMI). Such work will facilitate future mechanistic studies and expedite drug screening and proof-of-concept testing for Parkinson's therapeutics.

PPMI has generated and distributed iPSCs from a subset of its participants. These cell lines are coupled with robust clinical, imaging and biological data captured in the study. Recently, MJFF-funded scientists completed deep molecular phenotyping studies in dopaminergic neurons derived from these iPSCs. That data is also available.

This funding program aims to incorporate other molecular and functional phenotypic assays to further characterize the iPSCs/iPSC-derived cells from PPMI. Researchers from public and private institutions are encouraged to apply and to collaborate.

Program Priorities:
- Assessments of known PD targets and pathophysiologic pathways
- Assays to characterize functional, electrophysiological and/or neuroanatomical phenotypes
- Assays/endpoints that can be compared to biofluid data to determine the value of iPSCs as human disease models
- Comparative assessments across different cell types (e.g., neurons, glia)
- Assessments in co-culture systems to study cell autonomous and non-cell-autonomous phenotypes
- Contribution of aging to PD-relevant phenotypes
- Analyses of FOUNDIN-PD data

Citizenship: Unrestricted

Award Amount:
- Up to $200,000 for analysis of existing datasets
- Up to $1 million for phenotypic analysis

Indirect Costs: 15%
Preliminary Proposal Deadline: September 28, 2021
Research Management Deadline: January 3, 2022
(Invited) Proposal Deadline: January 13, 2022
Website: https://www.michaeljfox.org/funding-opportunities

11. MRI Biomarkers: Data Analysis and Tool Generation, The Michael J. Fox Foundation for Parkinson's Research (MJFF)

This funding program will support studies to develop reproducible diagnostic, prognostic, and monitoring magnetic resonance imaging (MRI) biomarkers.

Advances in MRI offer the opportunity to improve Parkinson's disease (PD) diagnosis and monitoring. But these measures still show significant overlap between PD and control volunteers. And patterns elucidated from group comparisons cannot yet be applied to individual patients for definitive diagnosis.

This program prioritizes three goals:
1. Modeling and analytics: leveraging existing imaging data to develop novel analyses methodology to (i) enable early detection of PD, (ii) identify imaging patterns unique to phenotypic subtypes of PD, and (iii) track disease progression and the efficacy of therapeutic intervention
2. Novel imaging sequences or post-processing techniques: developing and validating novel MRI sequences and novel post-processing techniques that provide insights into the mechanisms underlying PD
3. Tool and platform development: developing generalizable and easily deployable tools and platforms to enhance biomarker identification, disease classification and clinical decision making

Prospective data collection is only permitted for studies that utilize novel MRI sequences.

Citizenship: Unrestricted

Award Amount: $5 million for total program
Indirect Costs: 15%
Preliminary Proposal Deadline: September 28, 2021
Research Management Deadline: January 3, 2022
(Invited) Proposal Deadline: January 13, 2022
Website: https://www.michaeljfox.org/funding-opportunities

12. Parkinson's Pathway Molecular Data Analysis, The Michael J. Fox Foundation for Parkinson's Research (MJFF) NEW

This funding program will support high-impact projects that utilize existing data resources to increase molecular understanding of Parkinson's disease (PD), correlate biological changes to clinical/other outcomes, and more deeply interrogate disrupted pathways in PD.

The PD research field has generated a wealth of molecular data. This program aims to encourage projects to mine those data sets for biomarkers of Parkinson's progression, phenoconversion, diagnosis and patient stratification.

Program Priorities:
- Comparisons of analytes across complementary cohorts to identify or evaluate performance of putative biomarkers
- Evaluation of underexplored genetic variants associated with PD risk and correlates with clinical or molecular features of disease
- Identification of novel molecular indicators of phenoconversion and/or PD subtyping
- Integrated analysis of multi-omic data sets to identify and characterize critical pathways disrupted in PD
- Identification of novel genotype-phenotype implications on molecular features of disease
- Characterization of molecular indicators of the role of the immune system in PD risk and patient outcomes
- Identification or evaluation of molecular indicators of lysosomal and endosomal function, dysfunction or functional diversity relevant to PD risk and penetrance

This program is **not** appropriate for projects to:
- Generate new molecular, genetic or imaging data
- Support therapeutic development or identification of therapeutic compounds
- Solicit MJFF biosamples to conduct or expand ongoing analysis
- Replicate or review published work without novel analysis aims

Special consideration will be given to applications that integrate findings across data sets. Review an overview of the data presently available through MJFF-supported data platforms in the RFA Overview.

Eligibility requirements (partial list):
- Post-doctoral fellows are eligible to apply as co-investigators with the designation of an administrative primary investigator who directs the laboratory in which the fellow will conduct research. The administrative co-PI will be responsible for assisting in providing all institutional documents required for the project and will be required to sign any award contract. Training or mentoring-only proposals will not be considered.

Citizenship: Unrestricted

Award Amount: Up to $350,000
Indirect Costs: 15%
Preliminary Proposal Deadline: September 28, 2021
Research Management Deadline: January 3, 2022
(Invited) Proposal Deadline: January 13, 2022
Website: https://www.michaeljfox.org/funding-opportunities

13. Target Advancement Program, The Michael J. Fox Foundation for Parkinson's Research (MJFF)

This funding program — an Edmond J. Safra Core Program for PD Research — seeks to build conclusive evidence and develop field-enabling tools around early-stage biological targets in Parkinson's disease (PD).

Funding will support projects to validate early-stage targets previously implicated in PD pathophysiology and/or symptomology but that have not yet been rigorously investigated for their ability to impact disease-relevant outcomes in PD model systems. Replication studies are encouraged to build data that could increase confidence in starting therapeutic translational programs. Studies may request access to MJFF-sponsored biospecimen and cell line collections. For targets that are lacking pre-clinical tools and/or models, the Tool Generation track provides funding for the development of such resources to assist with the validation of the selected target. Please note, tools resulting from this funded work must be deposited in an MJFF-designated repository for community access after completion of the project.

We will not consider proposals focused on validation of established targets (alpha-synuclein, LRRK2, GBA, PRKN and PINK1) or proposing discovery studies to identify new targets.

Citizenship: Unrestricted

Award Amount: $200,000 paid over 18-24 months
Indirect Costs: 15%
Preliminary Proposal Deadline: September 28, 2021
Research Management Deadline: January 3, 2022
(Invited) Proposal Deadline: January 13, 2022
Website: https://www.michaeljfox.org/funding-opportunities

14. Therapeutic Pipeline Program: Pre-clinical Program, The Michael J. Fox Foundation for Parkinson's Research (MJFF)

This funding program — an Edmond J. Safra Core Program for PD Research — will support development of Parkinson's disease (PD) therapeutics with potential for fundamentally altering disease course or significantly improving non-motor or motor symptoms.

Please note, this round, we are funding only pre-clinical studies. We will review applications for clinical studies in future rounds of this program.

The Therapeutic Pipeline Program funds novel approaches and interventions as well as repurposed or repositioned therapies approved or clinically safe from other disease indications. Pharmacological and non-pharmacological therapies are encouraged to apply.

Program Priorities:
- Assay development, early screening campaigns, hit-to-lead and lead optimization
- Proof-of-concept
- Pharmacokinetics, pharmacodynamics and safety

Studies may request access to MJFF-sponsored biospecimen and cell line collections.

Citizenship: Unrestricted

Award Amount: Up to $500,000 paid over 1-2 years
Indirect Costs: 15%
Preliminary Proposal Deadline: September 28, 2021
Research Management Deadline: January 3, 2022
(Invited) Proposal Deadline: January 13, 2022
Website: https://www.michaeljfox.org/funding-opportunities